- Prescribing Information
- For US Patients
DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received at least one prior medicine to treat their multiple myeloma.
The main goal of the study was to measure the length of time patients lived without their multiple myeloma getting worse or passing away from any cause.
Another goal was to measure overall response rate, which is the percentage of patients who responded to treatment.
DARZALEX® in combination with Rd increased the time patients lived without their multiple myeloma getting worse.
of patients lived without their disease getting worse
with DARZALEX® + Rd (n=286) vs 59% of patients
treated with Rd alone (n=283).*
*At a median follow-up of 13.5 months.
More patients responded to DARZALEX® in combination with Rd vs Rd alone
91% of patients responded to DARZALEX® + Revlimid® + dexamethasone (DRd) (n=286) vs 75% of patients treated with Rd alone (n=283).
